Diabetes Care in The Netherlands: - Novo Nordisk

More documents

Recommendations

Info

3Recommendation 3: Engage the patient’s social network to supportself managementRecommendation 3: Engage the patient’s social network tosupport self managementBarrier Diagnosis RecommendationThe socialnetwork is notsystematicallyengaged inpatient’s care• Medical treatments for Diabetes Type 1 and Type 2can be effective, however compliance is a hugechallenge- Effects of non-compliance are severe- Non compliance is a challenge of distant benefits and largerequired behavioural change• Facilitated patient networks are successful in otherdistant benefits – high behavioural change conditions• Examples of patient networks for other conditions (e.g.obesitas) can be instructive for diabetes• Integrated behavioural interventions have beensuccessful in improving compliance (e.g. KaiserPermanente Evidence)Medical professionals: Includebehavioural dimension in medicalguidelines• Include family in standard treatment(e.g. family at key doctor visits)• Add checklist for aligning treatment withpersonal life (mass customization)Novo Nordisk: Scale-up social media• Scale-up diabetes health communitieswith patients and their professionals(mijn zorgpagina DVN, mijnzorgnet)Novo Nordisk: Educate amateur coachesfor non-adherent patients• Develop screening instrument forcoaching eligibility for physicians• Educate amateur coaches• Select professional coaches in aselected group of complicated casesBooz & Company 14 November 2011Prepared for Novo Nordisk916
44Recommendation 4: Introduce conditional market access modelsforRecommendationnew therapies4:andIntroducemedicationconditionalto assessmarketbehaviouralaccessimpactmodelsfor new therapies and medication to assess behavioural impactBarrier Diagnosis RecommendationDecisions oninsurancecoverage tendto undervaluebehaviouralimpact• Optimal treatment with current generation of diabetesmedication is therapeutically highly effective if patientsare compliant• But new medication could add a lot of value in boostingcompliance• CFH medication access criteria allow evaluation of impacton compliance, however the required evidence is usuallynot generated by trialsGovernment and insurer• Define models that allow forconditional access to proofindirect effects on compliance• Include compliance in theguidelines as a factor driving thechoice of medicationsBooz & Company 14 November 2011Prepared for Novo Nordisk1017
Page 6 and 7: SummaryDiabetes is a serious and de
Page 8: diabetes care. Extra compensation w
Page 11 and 12: ContentsSummarized findings and rec
Page 13 and 14: 11Diabetes is a major and underesti
Page 15 and 16: 33Further improving health of of di
Page 17: 22Recommendation 2: Engage employer
Page 21 and 22: Already more than 1M diabetes patie
Page 23 and 24: Costs of of complications and treat
Page 25 and 26: Number of patients reaches ~1.4M in
Page 27 and 28: Increase in lost productivity is dr
Page 29 and 30: Diabetes care clearly improved in t
Page 31 and 32: Better compliance can be stimulated
Page 37 and 38: Delaying complications saves medica
Page 39 and 40: LimitedLimitedcollaborationcollabor
Page 41 and 42: Individual quality incentives are l
Page 43 and 44: Recommendation 1: Insurer should in
Page 47 and 48: Labour shortage from late nineties
Page 49 and 50: However, curative and participative
Page 53 and 54: Non-compliance leads to severe comp
Page 55: Facilitated patient networks are su
Page 58 and 59: Recommendation 3:Facilitate network
Page 62 and 63: But new medication could add a lot
Page 66: Booz & Company is a global manageme

Diabetes Care in The Netherlands: - Novo Nordisk

Create successful ePaper yourself

Delete template?

Save as template?